Latest Abiraterone Stories
CHICAGO, June 3, 2011 /PRNewswire/ -- Data related to ZYTIGA(TM) (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time.
HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo.
HORSHAM, Pa., April 28, 2011 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that the U.S.
SILVER SPRING, Md., April 28, 2011 /PRNewswire-USNewswire/ -- The U.S.
HORSHAM, Pa., Dec. 20, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. has submitted a New Drug Application (NDA) to the U.S.
- In medieval musical notation, a sign or neume denoting a shake or trill.